Blood Disorder Therapeutics Market Global Research and Clinical Survey Report 2020

Global Blood Disorder Therapeutics Market - Growth, Trends, And Forecast (2020 - 2025)

The report presents an in-depth assessment of the Global Blood Disorder Therapeutics including enabling technologies, key trends, market drivers, challenges, standardization, regulatory landscape, deployment models, operator case studies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents forecasts for Global Blood Disorder Therapeutics investments from 2020 till 2025.

Click the link to get a Sample Copy of the Report:

https://www.marketinsightsreports.com/reports/04061950138/blood-disorder-therapeutics-market-growth-trends-and-forecast-2020-2025/inquiry?Source=OpenPr&Mode=RJ

The Global Blood Disorder Therapeutics market is highly competitive and consists of a number of major players. Companies, like Takeda Pharmaceutical Company Limited (Shire Plc), Sanofi, Novo Nordisk A/S, CSL Ltd, Pfizer Inc(NYSE: PFE), Bayer AG(ETR: BAYN), Celgene Corporation, Alexion Pharmaceuticals, Inc(NASDAQ: ALXN), Amgen Inc(NASDAQ: AMGN), AstraZeneca Plc among others.

Latest news and developments:

December 10, 2019 - A pivotal Phase 3 open-label, single-arm trial evaluating the safety and efficacy of sutimlimab in people with primary cold agglutinin disease (CAD) met its primary and secondary endpoints. These results were presented at the Late-Breaking Abstracts Session of the 61st Annual Meeting of the American Society of Hematology in Orlando, FL.

Sutimlimab is the first investigational treatment designed to selectively target and inhibit C1s in the classical complement pathway, a part of the immune system that is responsible for activating the mechanism of hemolysis in CAD. It has the potential to be the first approved therapy for this rare autoimmune hemolytic anemia. Sanofi intends to submit a Biologics License Application for sutimlimab, for which it has received Breakthrough Therapy designation, to the US Food and Drug Administration in the near future.

2 April 2020: AstraZeneca has completed the previously communicated agreement to sublicense its global rights to Movantik (naloxegol), excluding Europe, Canada and Israel, to RedHill Biopharma (RedHill). AstraZeneca will continue to manufacture and supply Movantik to RedHill during a transition period. In 2015, AstraZeneca entered into a co-commercialisation agreement with Daiichi Sankyo, Inc. for Movantik in the US, which has now been transferred to RedHill.

Market Overview:

The Blood Disorder Therapeutics Market is expected to register a CAGR of 6.2% during the forecast period. Blood disorders are conditions that impact the blood's ability to function correctly. It includes problems with the white blood cells, red blood cells, platelets, bone marrow, spleen, lymph nodes, and the proteins which are involved in bleeding and clotting (hemostasis and thrombosis). Most of the blood disorders are caused by mutations in specific genes and can be passed down in families. According to the National Heart, Lung, and Blood Institute, Hemophilia A is the most common type of the disease in males then females about 1 in 4,000 to 1 in 5,000 males worldwide are born with Hemophilia A disorder and Hemophilia B occurs in approximately 1 in 20,000 newborn males worldwide. As per study published in the PLOS Medicine Journal, sickle cell anemia cases are expected to increase about 30 percent globally by the year 2050. Rising prevalence of various blood disorders and increasing investment in research and development for advance treatment options are the key driving factors in blood disorder therapeutics market.

(Special Offer: Get flat upto 20% discount on this report)

Inquire for Discount:

https://www.marketinsightsreports.com/reports/04061950138/blood-disorder-therapeutics-market-growth-trends-and-forecast-2020-2025/discount?Source=OpenPr&Mode=RJ

Key Market Trends:

Recombinant Factors Segment is Expected to Hold a Significant Market Share in the Blood Disorder Therapeutics Market

- Worldwide, the rising prevalence of blood disorders and increasing adoption of recombinant factor concentrates are the key drivers of the recombinant factors segment.
- A recombinant factor is a form of blood factor that is manufactured via recombinant technology. Recombinant factors are used in the treatment of disorders such as hemophilia (prevention and control of hemorrhagic episodes).
- According to the World Federation of Hemophilia Report, in the year 2017, worldwide around 315,423 people are affected by bleeding disorders. Among them approximately 196,706 people are living with Hemophilia, 76,144 people with von Willebrand disease (VWD) and 42,573 with other bleeding disorders. Furthermore, according to the National Hemophilia Foundation, approximately 75% of people with hemophilia around the world still do not receive adequate treatment or have no access to treatment.
- Recombinant factors segment hold a significant market share by revenue and is anticipated to show steady growth over the forecast period due to the growing need to treat blood-related disorders and increase in production of recombinant products globally.

Browse the Full report description and TOC at:

https://www.marketinsightsreports.com/reports/04061950138/blood-disorder-therapeutics-market-growth-trends-and-forecast-2020-2025?Source=OpenPr&Mode=RJ

The key insights of the Blood Disorder Therapeutics Market report:

The report provides key statistics on the market status of the Blood Disorder Therapeutics market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.
The report provides a basic overview of the industry including its definition, applications and manufacturing technology.
The Blood Disorder Therapeutics market report presents the company profile, product specifications, capacity, production value, and 2015-2020 market shares for key vendors.
The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.
The report estimates 2020-2025 market development trends of Blood Disorder Therapeutics Market.
Analysis of upstream raw materials, downstream demand and current market dynamics is also carried out
The report makes some important proposals for a new project of Blood Disorder Therapeutics Industry before evaluating its feasibility.

Finally, Blood Disorder Therapeutics Market report is the believable source for gaining the market research that will exponentially accelerate your business. The report gives the principle locale, economic situations with the item value, benefit, limit, generation, supply, request and market development rate and figure and so on. Blood Disorder Therapeutics industry report additionally Present new task SWOT examination, speculation attainability investigation, and venture return investigation.

Browse Related Reports:

Inherited Orphan Blood Disorders Therapeutics Market

https://www.marketinsightsreports.com/reports/0815779146/global-and-chinese-inherited-orphan-blood-disorders-therapeutics-industry-2018-market-research-report?source=OpenPr&Mode=RJ

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format

- Report customization as per the client's requirements

- 3 months of analyst support

How we have factored the effect of Covid-19 in our report:

All the reports that we list have been tracking the impact of COVID-19. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

ABOUT US:
MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

CONTACT US:
Irfan Tamboli (Head of Sales) - Market Insights Reports
Phone: + 1704 266 3234 | +91-750-707-8687
sales@marketinsightsreports.com | irfan@marketinsightsreports.com

This release was published on openPR.